In the large‐volume tumor model, this nanovaccine exhibited potent antitumor efficacy, as evidenced by marked tumor suppression and increased tumor infiltration of CD8+ T cells, while maintaining favorable biosafety throughout the treatment period. The gene discussed is CD8A; the disease is neoplasm.